BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaumaya PT. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncol 2020;16:1767-91. [PMID: 32564612 DOI: 10.2217/fon-2020-0224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Palma M. Perspectives on passive antibody therapy and peptide-based vaccines against emerging pathogens like SARS-CoV-2. Germs 2021;11:287-305. [PMID: 34422699 DOI: 10.18683/germs.2021.1264] [Reference Citation Analysis]
2 Giacobino C, Canta M, Fornaguera C, Borrós S, Cauda V. Extracellular Vesicles and Their Current Role in Cancer Immunotherapy. Cancers (Basel) 2021;13:2280. [PMID: 34068657 DOI: 10.3390/cancers13092280] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Guo L, Overholser J, Good AJ, Ede NJ, Kaumaya PTP. Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys). Front Oncol 2022;12:826566. [DOI: 10.3389/fonc.2022.826566] [Reference Citation Analysis]
4 Sher YP, Chai KM, Chen WC, Shen KY, Chen IH, Lee MH, Chiu FF, Liu SJ. A Polypeptide of Tumor-Associated Antigen L6 with Intrinsic Adjuvant Activity Enhances Antitumor Immunity. Vaccines (Basel) 2020;8:E620. [PMID: 33096846 DOI: 10.3390/vaccines8040620] [Reference Citation Analysis]
5 Yong T, Chang K, Wang Y, Ma C. Active Humoral Response Reverts Tumorigenicity through Disruption of Key Signaling Pathway. Vaccines 2022;10:163. [DOI: 10.3390/vaccines10020163] [Reference Citation Analysis]
6 Guo L, Kaumaya PTP. First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations. Br J Cancer 2021;125:152-4. [PMID: 33772155 DOI: 10.1038/s41416-021-01342-9] [Reference Citation Analysis]